Category Archives: IP

The Strange Twists and Turns of 'Pay for Delay'

By Clark Herman | Published: January 30, 2013
In the arcane world of patent litigation, the term ‘pay for delay’ can be misleading, and as the Washington debate to restrict these deals unfolds, it is becoming apparent that a  ban on such settlements may serve to delay generics even further.  Is the fresh grass of reform really always greener than the well-seeded status [...]
Also posted in Legal, Market Access, Regulatory, Strategy | Tagged , | Leave a comment

R&D Trends for 2013: Data Trims, Partnerships, and Emerging Global Players

By Clark Herman | Published: January 14, 2013
The Tufts Center for the Study of Drug Development (CSDD) sees two key trends as increasingly important for pharmaceutical companies to maintain success: eliminating the bane of extraneous data and fostering collaborations with academia and multi-company consortia both as measures of reducing costs and remaining competitive by more quickly and effectively guiding medicines to market. [...]
Also posted in Emerging Markets, R&D, Strategy | Tagged , , | 1 Comment

The Orphan Drug Act at 30 Years: What's Next?

By Clark Herman | Published: January 8, 2013
30 years ago last week, the US Orphan Drug Act came into being, and with it, a door of possibilities opened up for patients with literally thousands of untreated diseases. The anniversary marks the beginning of a journey where medicines for rare diseases have gained a foothold in the portfolios of drug companies large and [...]
Also posted in Biotech, FDA, Orphan Drugs, Regulatory, Strategy | Tagged , , , , , , | Leave a comment

Pharma Forecast 2020: Cold Comfort

By Clark Herman | Published: November 16, 2012
Price Waterhouse Cooper’s “Pharma 2020: From vision to decision” parses a mix of gloomy and glowing scenarios that reflect the fickle, delicate nature of today’s industry. On the one hand, innovations in other areas such as mobile technology promise to breathe new life into pharma with cutting-edge initiatives. On the opposite end, stark fiscal realities [...]
Also posted in Emerging Markets, Europe, FDA, Global, R&D, Regulatory, Strategy, compliance, pricing | Leave a comment

Pharma in the Dell: Working with Academia

By Ben Comer | Published: November 14, 2012
How can the emerging field of data science help to fruitfully translate research and discovery into successful drug development? Academics and pharmaceutical executives at Mount Sinai’s School of Medicine discussed ways to build a bridge across the valley of death, and the growing importance of data across all business areas.
Also posted in Biotech, Deals, Meetings, People, R&D, Strategy, Technology, leadership | Tagged , , , , , , | Leave a comment